Steroids, salt supplements, and birth control are some of the treatment options for this condition. Learn more about what they do and the potential side effects.

for use in combination with glucocorticoids in the treatment of adults and children aged 4 years or older with classic congenital adrenal hyperplasia (CAH). In CAH, a genetic mutation causes ...

Crinetics Pharma reports positive results from phase 2 trial of atumelnant in congenital adrenal hyperplasia: San Diego Monday, January 13, 2025, 16:30 Hrs [IST] Crinetics Pharmac ...

Crinecerfont is an oral, selective corticotropin-releasing factor type 1 receptor antagonist that decreases adrenal androgen production by inhibiting adrenocorticotropic hormone secretion from the ...

Crinecerfont (Crenessity), a selective corticotropin-releasing factor type 1 receptor, is the first treatment for congenital adrenal hyperplasia (CAH) that directly reduces excess ...

Acting as a potent and selective oral corticotropin-releasing factor type 1 receptor (CRF1 ... advance for patients with classic congenital adrenal hyperplasia and highlights the FDA's continued ...

Additionally, rapid, substantial and sustained statistically significant reductions in 17-OHP, a confirmatory secondary biomarker of disease control, were achieved across doses. Treatment with ...

Atumelnant is currently in development for congenital adrenal hyperplasia and ACTH-dependent ... selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development ...

serious and lifelong genetic condition involving the adrenal glands. The company noted that CRENESSITY, a potent and selective oral corticotropin-releasing factor type 1 receptor (CRF1 ...

The FDA has granted priority review designation for two new drug applications for a selective corticotropin-releasing factor type 1 receptor to treat congenital adrenal hyperplasia, according to a ...